General Information of Drug (ID: DM9Y3B5)

Drug Name
CMX-001
Synonyms
Brincidofovir; CMX001; 444805-28-1; Hexadecyloxypropyl-cidofovir; CMX 001; Hexadecyloxypropyl cidofovir; UNII-6794O900AX; 6794O900AX; HDP-Cidofovir; Cidofovir-HDP; [(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethyl-(3-hexadecoxypropoxy)phosphinic acid; Brincidofovir [USAN:INN]; Hexadecyloxypropyl - cidofovir; Cidofovir prodrug; HDP-HPMPC; Brincidofovir (USAN); AC1LA8GF; 3-(hexadecyloxy)propyl hydrogen ((((S)-1-(4-amino-2-oxopyrimidin-1(2H)-yl)-3-hydroxypropan-2-yl)oxy)
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 3 [1]
Affected Organisms
Variola virusHuman Cytomegalovirus
ATC Code
J05AB17: CMX-001
J05AB: Nucleosides and nucleotides excl. reverse transcriptase inhibitors
J05A: DIRECT ACTING ANTIVIRALS
J05: ANTIVIRALS FOR SYSTEMIC USE
J: ANTIINFECTIVES FOR SYSTEMIC USE
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 2 Molecular Weight (mw) 561.7
Logarithm of the Partition Coefficient (xlogp) 4.9
Rotatable Bond Count (rotbonds) 26
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 7
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 3400 mcgh/L [2]
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 480 mcg/L [2]
Bioavailability
The bioavailability of drug is 13.4% [2]
Clearance
The clearance of drug is 44.1 L/h [2]
Elimination
The drug is eliminated as metabolites in both the urine (~51%) and feces (~40%) [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 19.3 hours [2]
Metabolism
The drug is metabolized via the carboxylation of the terminal carbon followed by several cycles of CYP-mediated oxidative reactions and fatty acid oxidation [2]
Vd
The volume of distribution (Vd) of drug is 1230 L [2]
Chemical Identifiers
Formula
C27H52N3O7P
IUPAC Name
[(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethyl-(3-hexadecoxypropoxy)phosphinic acid
Canonical SMILES
CCCCCCCCCCCCCCCCOCCCOP(=O)(CO[C@@H](CN1C=CC(=NC1=O)N)CO)O
InChI
InChI=1S/C27H52N3O7P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-19-35-20-16-21-37-38(33,34)24-36-25(23-31)22-30-18-17-26(28)29-27(30)32/h17-18,25,31H,2-16,19-24H2,1H3,(H,33,34)(H2,28,29,32)/t25-/m0/s1
InChIKey
WXJFKKQWPMNTIM-VWLOTQADSA-N
Cross-matching ID
PubChem CID
483477
CAS Number
444805-28-1
UNII
6794O900AX
DrugBank ID
DB12151
TTD ID
D0W5NW
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
DNA-dependent DNA polymerase (DPOL) TTATL6Y DPOLQ_HUMAN ; DPOLN_HUMAN ; DPOLB_HUMAN ; DPOG2_HUMAN ; DPOG1_HUMAN ; DPOE2_HUMAN ; DPOD4_HUMAN ; DPOD1_HUMAN Inhibitor [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT02087306) Phase III, Open-labeled, Multicenter Study of the Safety and Efficacy of Brincidofovir (CMX001) in the Treatment of Early Versus Late Adenovirus Infection. U.S. National Institutes of Health.
2 FDA Approved Drug Products: Tembexa (brincidofovir) for oral administration
3 Detection of Molluscum Contagiosum Virus (MCV) DNA in the Plasma of an Immunocompromised Patient and Possible Reduction of MCV DNA With CMX-001. J Infect Dis. 2012 March 1; 205(5): 794-797.